The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?
Locally advanced cervical cancer remains a significant therapeutic challenge, with high rates of recurrence and metastasis despite advances in chemoradiation. Immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, has emerged as a promising strategy to enhance treatm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573576/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035355169849344 |
|---|---|
| author | Fadila Kouhen Fadila Kouhen Fadila Kouhen Adil El Ghanmi Adil El Ghanmi Hanane Inghaoun Hayat Miftah Bouchra Ghazi Bouchra Ghazi Abdallah Badou |
| author_facet | Fadila Kouhen Fadila Kouhen Fadila Kouhen Adil El Ghanmi Adil El Ghanmi Hanane Inghaoun Hayat Miftah Bouchra Ghazi Bouchra Ghazi Abdallah Badou |
| author_sort | Fadila Kouhen |
| collection | DOAJ |
| description | Locally advanced cervical cancer remains a significant therapeutic challenge, with high rates of recurrence and metastasis despite advances in chemoradiation. Immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, has emerged as a promising strategy to enhance treatment efficacy. This review explores the integration of immunotherapy with standard chemoradiation, highlighting the potential of PD-1 inhibitors, such as pembrolizumab, in improving progression-free survival (PFS) among high-risk patients. Furthermore, the role of predictive biomarkers, including microsatellite instability (MSI) and tumor mutational burden (TMB), is examined to refine patient selection and personalize therapeutic approaches. Emerging strategies, including the use of nivolumab, ipilimumab, and maintenance immunotherapy, are also discussed. While preliminary clinical data are encouraging, further research is required to optimize treatment combinations, establish robust patient selection criteria, and enhance long-term outcomes in cervical cancer management. |
| format | Article |
| id | doaj-art-f4a52d6155fe4affbb7d724a1e64bb2b |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f4a52d6155fe4affbb7d724a1e64bb2b2025-08-20T02:57:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15735761573576The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Fadila Kouhen0Fadila Kouhen1Fadila Kouhen2Adil El Ghanmi3Adil El Ghanmi4Hanane Inghaoun5Hayat Miftah6Bouchra Ghazi7Bouchra Ghazi8Abdallah Badou9Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Rabat, MoroccoLaboratory of Neurooncology, Oncogenetic and Personalized Medicine, Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, MoroccoDepartment of Radiotherapy, International University Hospital Cheikh Khalifa, Casablanca, MoroccoImmunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, MoroccoDepartment of Gynecology and Obstetrics, Mohammed VI International University Hospital, Bouskoura, MoroccoLaboratory of Neurooncology, Oncogenetic and Personalized Medicine, Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, MoroccoLaboratory of Immunogenetics and Human Pathologies, Faculty of Medicine and Pharmacy, Casablanca, MoroccoImmunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, MoroccoDepartment of Gynecology and Obstetrics, Mohammed VI International University Hospital, Bouskoura, MoroccoLaboratory of Immunogenetics and Human Pathologies, Faculty of Medicine and Pharmacy, Casablanca, MoroccoLocally advanced cervical cancer remains a significant therapeutic challenge, with high rates of recurrence and metastasis despite advances in chemoradiation. Immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, has emerged as a promising strategy to enhance treatment efficacy. This review explores the integration of immunotherapy with standard chemoradiation, highlighting the potential of PD-1 inhibitors, such as pembrolizumab, in improving progression-free survival (PFS) among high-risk patients. Furthermore, the role of predictive biomarkers, including microsatellite instability (MSI) and tumor mutational burden (TMB), is examined to refine patient selection and personalize therapeutic approaches. Emerging strategies, including the use of nivolumab, ipilimumab, and maintenance immunotherapy, are also discussed. While preliminary clinical data are encouraging, further research is required to optimize treatment combinations, establish robust patient selection criteria, and enhance long-term outcomes in cervical cancer management.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573576/fullcervical cancerchemoradiationimmunotherapyimmune checkpoint inhibitorsclinical trialbiomarkers |
| spellingShingle | Fadila Kouhen Fadila Kouhen Fadila Kouhen Adil El Ghanmi Adil El Ghanmi Hanane Inghaoun Hayat Miftah Bouchra Ghazi Bouchra Ghazi Abdallah Badou The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? Frontiers in Immunology cervical cancer chemoradiation immunotherapy immune checkpoint inhibitors clinical trial biomarkers |
| title | The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? |
| title_full | The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? |
| title_fullStr | The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? |
| title_full_unstemmed | The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? |
| title_short | The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome? |
| title_sort | promise of pd1 pdl1 targeted immunotherapy in locally advanced cervical cancer a game changer for patients outcome |
| topic | cervical cancer chemoradiation immunotherapy immune checkpoint inhibitors clinical trial biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573576/full |
| work_keys_str_mv | AT fadilakouhen thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT fadilakouhen thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT fadilakouhen thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT adilelghanmi thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT adilelghanmi thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT hananeinghaoun thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT hayatmiftah thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT bouchraghazi thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT bouchraghazi thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT abdallahbadou thepromiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT fadilakouhen promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT fadilakouhen promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT fadilakouhen promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT adilelghanmi promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT adilelghanmi promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT hananeinghaoun promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT hayatmiftah promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT bouchraghazi promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT bouchraghazi promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome AT abdallahbadou promiseofpd1pdl1targetedimmunotherapyinlocallyadvancedcervicalcanceragamechangerforpatientsoutcome |